Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

PCR Biosystems Announces Next-generation of qPCR Reagents Push the Boundaries of Performance

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

PCR Biosystems has launched a new family of qPCR reagents mixes: Clara™ Probe Mix, Clara™ Probe 1-Step Mix and Clara™ HRM Mix. The cutting-edge Clara™ family of mixes rely on a novel composition to push the boundaries of performance to meet the challenges of today’s laboratories. Now, researchers can be more confident than ever before in the results they generate and the conclusions they assimilate.

qPCR is one of the most widely used techniques, globally. In research laboratories, qPCR assays are used for a diverse range of applications, such as gene expression analysis, species abundance quantification, cancer phenotyping and diagnostic test development. However, as a technique it is plagued by challenges surrounding reproducibility and reliability, leading to inefficient workflows and a lack of confidence in results. Researchers, therefore, typically look to improve qPCR performance to elucidate insights they can be confident in, while adhering to stricter budgets. Using carefully optimised, high-quality reagent mixes can overcome many hurdles and enhance qPCR performance.

“At PCR Biosystems, we’re committed to ensuring the highest level of performance is available to all, and that scientists from any discipline can access the reagents they need to advance their research.” explained Alex Wilson, Co-founder and Business Development Manager. “Having undergone rigorous testing, scientists can be confident that Clara™ reagent mixes deliver new levels of sensitivity and precision so they can focus on their research more and worry about the products they need less.” Alex continued, “We’re passionate about pushing the boundaries of PCR and our team of reagent specialists strive to unlock new levels of performance — of which the Clara™ family is a testament. Scientists using our products can therefore be sure of the highest quality reagents, as well as a personalised service to make sure they’re using the optimum reagents for their application.”

Being ISO 13485 certified, the mixes can also be used in diagnostic tests. Whether academic or industrial, the reagents bring several benefits to the laboratory:

  • Clara™ Probe Mix: Delivers clear and consistent results while streamlining real-time PCR workloads, no matter the application. The concentrated 4x mix provides maximum reliability in both single and multiplex assays and offers superior detection of DNA targets down to 1 pg/μL cDNA. The mix is also suitable for melt-curve analysis and is available in No-ROX, Lo-ROX, Hi-ROX and separate-ROX options.
  • Clara™ Probe 1-Step Mix: Easy-to-use, the single tube 4x RT-qPCR mix is suitable for universal probe-based detection of RNA and DNA targets in single and multiplex assays. With both DNA polymerase and reverse transcriptase in the same mastermix, the Probe 1-Step Mix makes qPCR as simple and streamlined as possible, allowing you to investigate RNA targets and conduct DNA quantification in the same run, while minimising the risk of contamination. The mix can detect down to four copies of target per 20 μL reaction.
  • Clara™ HRM Mix: Powered by third-generation DNA-intercalating SyGreen 2 dye, this 2x qPCR mix delivers superior performance to accurately detect genetic mutations, quickly identify genotypes based on SNPs or calculate percent methylation of a target region. A cost-effective option to alternative probe-based detection while offering enhanced allelic discrimination. Clara™ HRM Mix is compatible with qPCR thermocyclers from, but not exclusive to Applied Biosystems, Bio-Rad, Eppendorf, Illumina, Qiagen and Roche.

To speak to a member of the team and request free samples, visit the PCR Biosystems stand (B57, Hall 3) at Medica on 14-17 November where experts will be on hand to advise scientists on which reagent mix is most suited to their specific application and instrument set-up. Alternatively, visit our website today.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine